Ezetimib Vivanta: Uses, Dosage & Side Effects
A cholesterol absorption inhibitor containing ezetimibe, used to lower elevated cholesterol levels in patients with hypercholesterolemia, either alone or in combination with a statin
Ezetimib Vivanta contains the active substance ezetimibe (10 mg), a cholesterol absorption inhibitor that works by selectively blocking the uptake of dietary and biliary cholesterol in the small intestine. It is prescribed for patients with primary hypercholesterolemia – either alone when a statin is inappropriate or not tolerated, or in combination with a statin when diet and statin therapy alone are insufficient to reach target cholesterol levels. Ezetimibe is also approved for homozygous familial hypercholesterolemia (with a statin) and homozygous sitosterolemia (phytosterolemia). Taken once daily with or without food, ezetimibe can reduce LDL cholesterol by approximately 18–20% as monotherapy and by an additional 25% when added to statin treatment. The landmark IMPROVE-IT trial established that adding ezetimibe to statin therapy reduces the risk of major cardiovascular events.
Quick Facts: Ezetimib Vivanta
Key Takeaways
- Ezetimib Vivanta (ezetimibe 10 mg) lowers cholesterol by blocking its absorption in the small intestine through the NPC1L1 transporter, complementing statins which reduce cholesterol production in the liver.
- The IMPROVE-IT trial demonstrated that adding ezetimibe to statin therapy significantly reduces major cardiovascular events in high-risk patients, establishing a firm evidence base for combination therapy.
- Ezetimibe is taken once daily with or without food, requires no dose adjustment for mild-to-moderate kidney impairment, and is generally well tolerated with a side effect profile similar to placebo in monotherapy.
- Do not use ezetimibe during pregnancy or breastfeeding; when combined with a statin, liver function tests should be monitored and any unexplained muscle pain reported immediately.
- International guidelines (ESC/EAS 2019, ACC/AHA) recommend ezetimibe as second-line add-on therapy when maximum tolerated statin doses do not achieve LDL cholesterol targets, before considering PCSK9 inhibitors.
What Is Ezetimib Vivanta and What Is It Used For?
Ezetimib Vivanta belongs to a class of lipid-lowering medications known as cholesterol absorption inhibitors. Unlike statins, which reduce cholesterol by inhibiting its production in the liver (via HMG-CoA reductase), ezetimibe targets a completely different pathway: it selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein, a sterol transporter located at the brush border of the small intestine. The NPC1L1 transporter is the critical gateway through which dietary cholesterol and cholesterol excreted in bile are reabsorbed into the body. By blocking this transporter, ezetimibe reduces the amount of cholesterol delivered from the intestine to the liver.
When less cholesterol arrives at the liver from the intestine, the liver responds by upregulating its LDL receptors – specialized proteins on the liver cell surface that capture LDL cholesterol (often called “bad cholesterol”) from the bloodstream. The net result is a measurable reduction in circulating LDL cholesterol levels. As monotherapy, ezetimibe typically reduces LDL cholesterol by approximately 18–20%. When combined with a statin, the two drugs work synergistically: the statin inhibits cholesterol synthesis while ezetimibe blocks cholesterol absorption, resulting in LDL cholesterol reductions of 45–65% depending on the statin and dose used.
Ezetimib Vivanta is approved for the following indications, always as an adjunct to dietary measures:
- Primary hypercholesterolemia: Ezetimibe is used in combination with a statin (such as atorvastatin, simvastatin, or rosuvastatin) in patients whose cholesterol levels are not adequately controlled by a statin alone. It may also be used as monotherapy in patients for whom a statin is considered inappropriate or is not tolerated – for example, patients who experience statin-related muscle symptoms (myalgia) at any statin dose.
- Homozygous familial hypercholesterolemia (HoFH): Ezetimibe is used in combination with a statin for patients with this rare genetic condition characterized by extremely high LDL cholesterol levels from birth. In HoFH, adding ezetimibe to maximum-dose statin therapy provides additional LDL lowering, though patients typically also require other treatments such as PCSK9 inhibitors or lipoprotein apheresis.
- Homozygous sitosterolemia (phytosterolemia): This is a rare inherited lipid disorder in which plant sterols (sitosterol and campesterol) are hyperabsorbed from the intestine and inadequately excreted by the liver into bile. Ezetimibe is uniquely effective in this condition because it blocks the NPC1L1 transporter that is responsible for the excessive absorption of both cholesterol and plant sterols.
The role of ezetimibe in cardiovascular risk reduction was firmly established by the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) study, published in the New England Journal of Medicine in 2015. This landmark trial enrolled over 18,000 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days. Patients were randomized to receive either simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo. Over a median follow-up of 6 years, the addition of ezetimibe to simvastatin reduced the primary composite endpoint (cardiovascular death, major coronary events, or non-fatal stroke) by 6.4% in relative terms, translating to a significant absolute risk reduction. This was the first trial to demonstrate that lowering LDL cholesterol below statin-achievable levels with a non-statin agent provides incremental cardiovascular benefit, supporting the “lower is better” paradigm for LDL cholesterol management.
Ezetimibe and statins work through complementary pathways. When a statin reduces liver cholesterol production, the body compensates by increasing intestinal cholesterol absorption. Adding ezetimibe blocks this compensatory increase, making the combination particularly effective. This is why international guidelines recommend ezetimibe as the preferred first add-on therapy when statins alone are insufficient.
What Should You Know Before Taking Ezetimib Vivanta?
Contraindications
There are specific situations in which Ezetimib Vivanta must not be used. Understanding these absolute contraindications is essential for safe treatment.
- Hypersensitivity: Do not take Ezetimib Vivanta if you are allergic to ezetimibe or any of the other ingredients in the tablets. Allergic reactions including rash, urticaria, and very rarely anaphylaxis have been reported.
- Active liver disease (with statin co-administration): When ezetimibe is used in combination with a statin, the combination must not be used in patients with active liver disease or unexplained persistent elevations of serum transaminases. This restriction is primarily driven by the statin component, but liver function monitoring is important for the combination.
- Pregnancy and breastfeeding (with statin co-administration): The combination of ezetimibe with a statin is strictly contraindicated during pregnancy and breastfeeding because statins can harm the developing fetus. Even as monotherapy, ezetimibe should not be used during pregnancy due to insufficient safety data.
Warnings and Precautions
Before and during treatment with Ezetimib Vivanta, discuss the following with your doctor:
- Liver function: If you have moderate or severe hepatic impairment (liver disease), ezetimibe is not recommended because its exposure may be increased. When ezetimibe is used with a statin, liver function tests (transaminases) should be performed before starting treatment and periodically thereafter as clinically indicated. If transaminase elevations exceed three times the upper limit of normal, treatment should be discontinued.
- Muscle effects (myopathy/rhabdomyolysis): Although ezetimibe alone has a very low risk of muscle problems, the combination with a statin carries the known statin-related risk of myopathy and, very rarely, rhabdomyolysis (severe muscle breakdown that can lead to kidney damage). Report any unexplained muscle pain, tenderness, or weakness to your doctor immediately, especially if accompanied by fever or malaise. The risk is increased at higher statin doses and with concomitant use of certain interacting drugs.
- Fibrate co-administration: The safety and efficacy of ezetimibe used together with fibrates (such as fenofibrate or gemfibrozil) have not been established. Fibrates can increase cholesterol excretion into bile and may increase the risk of gallstones. Until more data are available, the combined use of ezetimibe with fibrates is not recommended. If gallstone-like symptoms occur (upper abdominal pain, nausea), investigation is warranted.
- Ciclosporin (cyclosporine): If you are taking ciclosporin (an immunosuppressant used after organ transplantation and for certain autoimmune conditions), caution is required because ciclosporin can significantly increase ezetimibe blood levels, potentially increasing the risk of side effects. Monitoring of ciclosporin levels and ezetimibe exposure is recommended.
- Anticoagulants (warfarin): If you are taking warfarin or another coumarin anticoagulant, your INR (International Normalized Ratio) should be monitored appropriately when ezetimibe is added to or withdrawn from your treatment, as changes in cholesterol-lowering therapy can affect warfarin metabolism.
Pregnancy and Breastfeeding
Ezetimib Vivanta must not be used during pregnancy. There are no adequate and well-controlled studies of ezetimibe in pregnant women. Since cholesterol and other products of cholesterol biosynthesis are essential for normal fetal development, the potential risk of inhibiting cholesterol absorption during pregnancy outweighs any therapeutic benefit. Animal studies have not shown direct harmful effects on fertility or fetal development at clinically relevant doses, but as a precautionary measure, ezetimibe should not be used by women who are pregnant or may become pregnant.
If you discover you are pregnant while taking Ezetimib Vivanta, discontinue treatment immediately and consult your doctor. If you are taking ezetimibe in combination with a statin, discontinuation is even more critical because statins are known teratogens (category X).
It is not known whether ezetimibe is excreted in human breast milk. Animal studies have shown that ezetimibe passes into breast milk. Because of the potential for adverse effects in the nursing infant, a decision must be made whether to discontinue breastfeeding or discontinue ezetimibe, taking into account the importance of the drug to the mother. Ezetimibe should not be used during breastfeeding.
Driving and Operating Machinery
Ezetimibe is not expected to affect the ability to drive or operate machinery. No studies on the effect on the ability to drive and use machines have been performed. However, dizziness has been reported as an uncommon side effect. If you experience dizziness while taking Ezetimib Vivanta, do not drive or use machines until the symptom resolves.
How Does Ezetimib Vivanta Interact with Other Drugs?
Ezetimibe is metabolized primarily through glucuronide conjugation (a Phase II reaction) in the small intestine and liver, rather than through the cytochrome P450 enzyme system. This means it has a relatively low potential for pharmacokinetic drug interactions compared with many other lipid-lowering medications. Nevertheless, several clinically relevant interactions have been identified and should be considered.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Ciclosporin (Cyclosporine) | Increased ezetimibe blood levels (up to 3–12 fold); ciclosporin levels may also be affected | Use with caution; monitor ciclosporin levels and watch for ezetimibe side effects |
| Cholestyramine (bile acid sequestrant) | Reduces ezetimibe absorption by approximately 55% | Take ezetimibe at least 2 hours before or 4 hours after cholestyramine |
| Fibrates (fenofibrate, gemfibrozil) | May increase cholesterol excretion into bile; increased risk of gallstones; gemfibrozil increases ezetimibe exposure | Combination not recommended until safety data are available |
| Warfarin (coumarin anticoagulants) | Potential for altered INR when ezetimibe is added or withdrawn | Monitor INR when starting or stopping ezetimibe in patients on warfarin |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Statins (atorvastatin, simvastatin, rosuvastatin, etc.) | No clinically significant pharmacokinetic interaction; additive lipid-lowering efficacy | Intentional combination; monitor liver function and muscle symptoms |
| Antacids | Marginal reduction in ezetimibe absorption rate; no significant effect on overall exposure | No dose adjustment needed |
| Oral contraceptives (ethinylestradiol, levonorgestrel) | No significant interaction observed in clinical studies | No dose adjustment needed; contraceptive efficacy is maintained |
| Digoxin | No significant interaction observed | No dose adjustment needed |
Because ezetimibe is metabolized primarily by glucuronidation rather than the cytochrome P450 system, it does not significantly affect the metabolism of drugs processed by CYP1A2, CYP2D6, CYP2C8, CYP2C9, or CYP3A4. This favourable metabolic profile means that ezetimibe can be safely combined with a wide range of commonly used medications without the complex drug interaction concerns that characterize some other lipid-lowering agents.
When ezetimibe is combined with a statin, the drug interaction profile of the statin also applies. For example, simvastatin has significant interactions with strong CYP3A4 inhibitors (such as itraconazole, ketoconazole, and HIV protease inhibitors), and these interactions remain relevant when the patient is also taking ezetimibe. Always inform your doctor and pharmacist of all medications, supplements, and herbal products you are taking.
What Is the Correct Dosage of Ezetimib Vivanta?
Ezetimib Vivanta has a straightforward dosing regimen. The dose is the same across all approved indications and for all adult patient populations, which simplifies prescribing and reduces the risk of dosing errors.
Adults
Standard Adult Dose
Dose: 10 mg once daily, taken orally
Administration: Swallow the tablet whole with water. Can be taken with or without food, at any time of day. However, taking it at the same time each day helps maintain consistent drug levels and improves adherence.
Duration: Ezetimibe is intended for long-term use. Cholesterol management is a lifelong endeavour, and discontinuing treatment will result in cholesterol levels returning to pre-treatment values. Continue taking the medication even if your cholesterol levels have improved, unless your doctor advises otherwise.
Diet: You should continue following a cholesterol-lowering diet (low in saturated fat and dietary cholesterol) throughout treatment. The diet provides the foundation of lipid management, and ezetimibe is most effective when used as an adjunct to dietary measures.
With Statin Combination
Dose: Ezetimibe 10 mg once daily, taken simultaneously with or separately from the statin. The statin dose is determined independently by the prescribing physician based on the patient’s LDL cholesterol target and risk profile.
Note: When starting combination therapy, it is common practice to initiate both drugs together. However, some guidelines recommend starting the statin first and adding ezetimibe after 4–6 weeks if the LDL cholesterol target has not been reached.
Children and Adolescents
Paediatric Use (Age 6 Years and Older)
Dose: 10 mg once daily for children aged 6 years and older with heterozygous familial hypercholesterolemia or sitosterolemia.
Note: Ezetimibe is not recommended for children under 6 years of age due to insufficient data. In children with HoFH, the same 10 mg dose may be used in combination with a statin from age 10 years. Lipid-lowering treatment in children should always be initiated and supervised by a specialist experienced in paediatric lipidology.
Elderly Patients
Elderly Patients (65 Years and Older)
Dose: 10 mg once daily. No dose adjustment is required for elderly patients.
Note: Clinical studies included patients up to 80 years of age and showed no difference in the safety or efficacy of ezetimibe between older and younger adults. The IMPROVE-IT trial showed cardiovascular benefit in elderly subgroups. However, elderly patients are more likely to have impaired liver or kidney function and to be taking multiple medications, so monitoring is important.
Renal and Hepatic Impairment
Kidney and Liver Function
Renal impairment: No dose adjustment is necessary for patients with mild, moderate, or severe renal impairment. However, patients on haemodialysis may have increased drug exposure, and caution is advised when starting ezetimibe in this population.
Mild hepatic impairment (Child-Pugh A): No dose adjustment is required.
Moderate to severe hepatic impairment (Child-Pugh B or C): Ezetimibe is not recommended due to potentially increased drug exposure and insufficient clinical experience in these populations.
Missed Dose
If you forget to take a dose, take it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and take your next dose at the usual time. Do not take a double dose to make up for a forgotten one. Missing an occasional dose is unlikely to significantly affect your overall cholesterol-lowering treatment, but consistent daily dosing is important for optimal results.
Overdose
In clinical studies, ezetimibe has been administered at doses of up to 40 mg per day to 18 patients and up to 50 mg per day to 5 patients for up to 2 weeks, without significant adverse effects. Ezetimibe is generally well tolerated even at supratherapeutic doses. In the event of an overdose, supportive and symptomatic treatment should be provided. There is no specific antidote. Due to extensive protein binding, ezetimibe is unlikely to be removed by haemodialysis. If you suspect an overdose, contact your doctor or poison control centre.
What Are the Side Effects of Ezetimib Vivanta?
Like all medicines, Ezetimib Vivanta can cause side effects, although not everyone experiences them. In clinical trials, the overall incidence of side effects with ezetimibe monotherapy was similar to that of placebo, indicating an excellent general tolerability profile. However, when ezetimibe is used in combination with a statin, the side effect profile also includes those associated with statin therapy.
The following side effects have been reported with ezetimibe, organized by frequency according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), and not known (cannot be estimated from available data).
Ezetimibe Monotherapy
Common
Affects 1 to 10 in every 100 people
- Headache
- Abdominal pain
- Diarrhoea
- Flatulence (gas)
- Fatigue
Uncommon
Affects 1 to 10 in every 1,000 people
- Elevated liver enzymes (ALT, AST)
- Elevated creatine phosphokinase (CPK)
- Muscle pain (myalgia)
- Nausea
- Dizziness
- Paraesthesia (tingling or numbness)
- Dry mouth
- Gastritis (stomach inflammation)
- Itching (pruritus)
- Rash and urticaria (hives)
- Joint pain (arthralgia)
- Muscle spasms
- Neck pain
- Decreased appetite
- Hot flushes
- Elevated blood pressure
Ezetimibe Combined with a Statin
Common
Affects 1 to 10 in every 100 people
- Headache
- Muscle pain (myalgia)
- Elevated liver enzymes (ALT, AST)
- Fatigue
- Abdominal pain
- Constipation
- Diarrhoea
- Flatulence
- Nausea
Uncommon
Affects 1 to 10 in every 1,000 people
- Elevated creatine phosphokinase (CPK)
- Dizziness
- Tingling or numbness (paraesthesia)
- Dry mouth
- Itching
- Rash
- Pain in extremities
- Muscle weakness
- Back pain
- Asthenia (general weakness)
Post-Marketing Reports (Rare and Very Rare)
Rare and Very Rare
Affects fewer than 1 in 1,000 people; reported after market authorization
- Thrombocytopenia (low platelet count)
- Hypersensitivity reactions including anaphylaxis and angioedema
- Pancreatitis (inflammation of the pancreas)
- Hepatitis (liver inflammation)
- Cholelithiasis (gallstones)
- Cholecystitis (gallbladder inflammation)
- Stevens-Johnson syndrome
- Erythema multiforme
- Myopathy and rhabdomyolysis (especially with statin combination)
- Depression
Contact your doctor immediately or seek emergency medical care if you experience: unexplained muscle pain, tenderness, or weakness (especially with fever or malaise, which may indicate rhabdomyolysis); signs of a severe allergic reaction (swelling of the face, lips, tongue, or throat; difficulty breathing; severe rash); severe abdominal pain (which may indicate pancreatitis); or yellowing of the skin and eyes (which may indicate hepatitis).
If you experience any side effect that is bothersome or that does not go away, talk to your doctor or pharmacist. You can also report side effects directly to your national adverse drug reaction reporting system. By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Ezetimib Vivanta?
Proper storage of medications is essential to ensure their effectiveness and safety throughout their shelf life. Ezetimib Vivanta tablets should be stored according to the following recommendations:
- Temperature: Store below 30°C (86°F). Do not refrigerate or freeze. Room temperature storage in a consistently temperate environment is ideal.
- Moisture protection: Keep the tablets in the original blister packaging or bottle to protect them from moisture. Do not transfer the tablets to another container unless it provides equivalent protection.
- Light protection: No special light protection requirements, but it is good practice to store medications away from direct sunlight.
- Child safety: Keep this medicine out of the sight and reach of children. Store in a secure location, ideally in a locked medicine cabinet.
- Expiry date: Do not use Ezetimib Vivanta after the expiry date (EXP) stated on the blister, bottle, and carton. The expiry date refers to the last day of that month.
- Disposal: Do not throw unused medicines down the drain or in household waste. Return unused or expired medicines to your pharmacy for safe disposal. This helps protect the environment.
If you notice any change in the appearance of the tablets (such as discolouration, crumbling, or unusual odour), do not take them and consult your pharmacist.
What Does Ezetimib Vivanta Contain?
Active Ingredient
Each film-coated tablet contains 10 mg ezetimibe. Ezetimibe (chemical name: 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone) is a white, crystalline powder with a molecular weight of 409.4 g/mol. It is practically insoluble in water and freely soluble in ethanol, methanol, and acetone.
Inactive Ingredients (Excipients)
The inactive ingredients serve various pharmaceutical functions such as binding, disintegration, lubrication, and coating. Common excipients in ezetimibe tablets include:
- Lactose monohydrate (filler/diluent)
- Microcrystalline cellulose (binder/filler)
- Croscarmellose sodium (disintegrant)
- Sodium lauryl sulfate (wetting agent)
- Magnesium stearate (lubricant)
- Hypromellose (film-coating)
- Titanium dioxide (E171, coating pigment)
- Macrogol/polyethylene glycol (coating plasticizer)
Ezetimib Vivanta tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Appearance
Ezetimib Vivanta 10 mg tablets are white to off-white, round or capsule-shaped film-coated tablets. They are supplied in blister packs or HDPE bottles, with pack sizes varying by market. Each package contains a package leaflet with full prescribing information.
Frequently Asked Questions About Ezetimib Vivanta
Ezetimib Vivanta contains ezetimibe 10 mg and is used to lower elevated cholesterol levels. It works by blocking the absorption of cholesterol in the small intestine. It is prescribed for primary hypercholesterolemia (alone when a statin is inappropriate or not tolerated, or in combination with a statin when statin alone is insufficient), homozygous familial hypercholesterolemia (with a statin), and homozygous sitosterolemia (phytosterolemia). It should always be used alongside a cholesterol-lowering diet.
Yes, and this is in fact the most common way ezetimibe is used. The combination of ezetimibe with a statin targets two complementary pathways: statins reduce cholesterol production in the liver while ezetimibe blocks cholesterol absorption in the intestine. The IMPROVE-IT trial proved that this combination not only lowers cholesterol more effectively but also reduces the risk of major cardiovascular events. International guidelines recommend adding ezetimibe to a statin when maximum tolerated statin doses do not achieve LDL cholesterol targets.
When ezetimibe is used alone, the most common side effects include headache, abdominal pain, diarrhoea, flatulence, and fatigue. These effects are generally mild and similar in frequency to placebo in clinical trials. When combined with a statin, additional common side effects may include muscle pain (myalgia), elevated liver enzymes, constipation, and nausea. Serious side effects are rare but include pancreatitis, hepatitis, gallstones, allergic reactions, and rhabdomyolysis. Report any unexplained muscle pain or weakness to your doctor promptly.
Ezetimibe begins reducing cholesterol absorption within the first 1–2 days of treatment. Measurable reductions in LDL cholesterol on blood tests are typically seen within 2 weeks. The full lipid-lowering effect is usually apparent after approximately 4 weeks of consistent daily use. Your doctor will typically check your cholesterol levels after 4–12 weeks of treatment to assess the response and determine whether adjustments to your lipid-lowering regimen are needed.
No. Ezetimib Vivanta must not be used during pregnancy or breastfeeding. There are insufficient data on the use of ezetimibe in pregnant women, and cholesterol is essential for fetal development. If you become pregnant or plan to become pregnant, stop taking ezetimibe and consult your doctor. This is especially critical if you are taking ezetimibe in combination with a statin, as statins are known to cause birth defects and are strictly contraindicated in pregnancy.
Yes, when added to statin therapy. The landmark IMPROVE-IT trial showed that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite endpoint of cardiovascular death, major coronary events, and non-fatal stroke by 6.4% compared with simvastatin alone over a median follow-up of 6 years in patients with recent acute coronary syndrome. This was the first trial to prove that lowering LDL cholesterol below statin-achievable levels with a non-statin drug provides additional cardiovascular protection. Based on this evidence, international guidelines now recommend ezetimibe as second-line add-on therapy.
References
- European Medicines Agency (EMA). Ezetimibe – Summary of Product Characteristics. Available from: EMA.
- U.S. Food and Drug Administration (FDA). Zetia (ezetimibe) Prescribing Information. Available from: FDA Drug Label.
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). N Engl J Med. 2015;372(25):2387–2397. doi:10.1056/NEJMoa1410489.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350. doi:10.1016/j.jacc.2018.11.003.
- Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943–1948. doi:10.1161/01.CIR.0000034044.95911.DC.
- Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201–1204. doi:10.1126/science.1093131.
- Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P. Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol. 2015;201:247–252. doi:10.1016/j.ijcard.2015.08.103.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- British National Formulary (BNF). Ezetimibe. National Institute for Health and Care Excellence (NICE). Available from: BNF.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in cardiology, lipidology, and clinical pharmacology.
Medical Content
iMedic Cardiology Editorial Team – specialist physicians in cardiology and internal medicine with clinical experience in lipid management
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, ESC/EAS, and ACC/AHA guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.